Assembly Biosciences, Inc. (ASMB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
331 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
833 509 4583
Website
Sector
Healthcare
Industry
Biotechnology
Employees
73
First IPO Date
December 17, 2010
| Name | Title | Pay | Year Born |
| Jason A. Okazaki | Chief Executive Officer, President & Director | 1.25M | 1976 |
| Thomas E. Rollins | Executive Officer | 472,550 | 1956 |
| Nicole S. White | Chief Manufacturing Officer | 655,840 | 1980 |
| Anuj Gaggar | Chief Medical Officer | 820,673 | 1978 |
| William E. Delaney | Chief Scientific Officer | 829,367 | 1972 |
| Amy Figueroa | Investor Relations Consultant | 0 | N/A |
| Katie Kitrinos | Senior Vice President of Preclinical Research & Development | 0 | N/A |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | 0 | N/A |
| Jennifer A. Troia MHROD SHRM-SCP SPHR | Chief Human Resources Officer | 0 | N/A |
| Jeanette Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | 0 | 1987 |
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.